Date: 2014-09-22
Type of information: Presentation of results at a congress
phase: 1b
Announcement:
Company: Roche (Switzerland)
Product: MPDL3280A (atezolizumab) and Avastin® (bevacizumab)
Action
mechanism: immunotherapy product/monoclonal antibody/immune checkpoint inhibitor. Anti-PDL1 antibody MPDL3280A is an investigational monoclonal antibody designed to make cancer cells more vulnerable to the body’s immune system by interfering with a protein called PD-L1. PD-L1 is found on the surface of cells in tumours and is believed to act as a “stop sign,” preventing the immune system from destroying cancer cells. By inhibiting PD-L1, MPDL3280A may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells. MPDL3280A is being studied in clinical trials to understand whether blocking PD-L1 will help the immune system respond to cancer. monoclonal antibody. Avastin® is an antibody that specifically binds and blocks the biological effects of VEGF (vascular endothelial growth factor), the key driver of tumor angiogenesis.
Disease: metastatic renal cell carcinoma
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On September 29, 2014, Roche announced the first combination data of MPDL3280A and Avastin® in untreated patients with metastatic renal cell carcinoma (mRCC). Results from the phase Ib study showed that the combination of MPDL3280A and Avastin was well tolerated and shrank tumours (ORR) in 40 percent (4/10) of people with previously untreated mRCC. Furthermore, preliminary data with monotherapy show that in pretreated mRCC, patients who had levels of PD-L1 expression (IHC1/2/3) were more likely to respond to MPDL3280A versus patients with no detectable expression of PD-L1 (IHC 0), 20 percent (n=35) versus 10 percent (n=21) respectively. The overall response rates for these patients was 15 percent (n=62). The primary objectives of these phase 1 cohort groups were safety and tolerability, with secondary objectives including ORR and duration of response (DOR).
